

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/30, 15/85, C07K 14/445, A61K 39/015</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/34105</b> <b>(43) International Publication Date:</b> 31 October 1996 (31.10.96)
<b>(21) International Application Number:</b> PCT/EP96/01744 <b>(22) International Filing Date:</b> 25 April 1996 (25.04.96) <b>(30) Priority Data:</b> 95201066.8 25 April 1995 (25.04.95) EP <b>(34) Countries for which the regional or international application was filed:</b> NL et al. 1001348 5 October 1995 (05.10.95) NL  <b>(71) Applicant (for all designated States except US):</b> RMF DIC-TAGENE S.A. [CH/CH]; Chemin des Passiaux 9, CH-1008 Prilly (CH).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FASEL, Nicolas, Joseph [CH/CH]; Bois Murat 30, CH-1006 Epalinges (CH). REY-MOND, Christophe, Dominique [CH/CH]; Chemin des Passiaux 9, CH-1008 Prilly (CH).  <b>(74) Agent:</b> VAN SOMEREN, Petronella, Francisca, Hendrika, Maria; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).			<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> MODIFIED POLYPEPTIDES FOR ENHANCED IMMUNOGENICITY			
<b>(57) Abstract</b>  The invention relates to a recombinant polypeptide showing enhanced immunogenicity, comprising a glycosyl-phosphatidylinositol structure. The polypeptide is for example an antigen, such as a parasite polypeptide, in particular a <i>Plasmodium falciparum</i> polypeptide, such as the circumsporozoite protein (CSP). The invention further relates to a recombinant DNA vector for expressing the polypeptide, methods of inducing an immune response directed to one or more epitopes of the polypeptide, and methods for the production of the modified polypeptides vaccines, comprising the polypeptide.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## MODIFIED POLYPEPTIDES FOR ENHANCED IMMUNOGENICITY

5

The present invention relates to modified polypeptides showing enhanced immunogenicity, in particular to polypeptides modified by a lipidic structure. In particular it relates to parasite polypeptides modified by a  
10 lipidic structure and more particular to the circumsporozoite protein of Plasmodium falciparum modified by such a lipidic structure. The invention further relates to a method for inducing an immune response against the modified polypeptides, to a method, vector and host for  
15 producing the polypeptides and to vaccines comprising the polypeptide.

The immune system is complex and not fully understood. The way by which foreign immunogens are recognized by the host immune system is only partially  
20 elucidated. The immune response of mammals exposed to foreign proteins varies to a large extent. Any method to prepare polypeptides with increased immunogenicity is therefore of great interest, overcoming otherwise weakly immunogenic epitopic sites.

25 One way to improve vaccination with recombinant proteins was to produce multiple epitopic sites from more than one protein originating from one or multiple infectious agents. This approach allows to obtain less expensive polyvalent, more efficient vaccines leading to simpler and  
30 safer immunization regimens. However, such an approach implies that every polypeptide is produced in sufficient amounts, requiring specific purification protocols for each polypeptide used for immunization insuring optimal quantity. It is challenging to find approaches where a strong immune  
35 response against specific epitopes is induced whereas the immunogens are in low quantity or present in a mixture of other polypeptides like it is observed in certain in vivo situations.

Plasmodium falciparum, the most frequent malaria causative agent, is found in different forms in insect and human hosts. The use of inactivated parasite forms as vaccine in mammals has shown promising results. A major  
5 limitation, however, is the fact that sporozoites cannot be cultivated and have to be isolated from mosquito salivary glands precluding the use of inactivated parasite as such to obtain protection.

To circumvent this problem, genes encoding  
10 specific proteins of different Plasmodium forms have been expressed in heterologous recombinant systems and used as potential host protective antigens, with limited success. Alternatively, peptides corresponding to defined regions of the antigens have been used in protection studies, showing  
15 the limitation of such immunizations. The circumsporozoite protein (CSP) is one of the antigens present at the surface of the Plasmodium falciparum sporozoite found in the organism after insect bite transmission. This protein is synthesized as a polypeptide precursor composed of an amino  
20 terminal signal sequence removed upon processing, of a large central repeat domain flanked on both sides by regions referred as region I and region II containing conserved sequences between different Plasmodia species and of an hydrophobic terminal carboxy domain. The repeat domain NANP  
25 consisting of a tandem repeat of the amino acid cluster asparagine-alanine-asparagine-proline ((ASN-ALA-ASN-PRO)<sub>n</sub>) has been shown to be an effective B-cell epitope of P.falciparum CSP. Synthetic peptides containing such a repeat have been used with limited success as subunit  
30 vaccine in protection studies. The T-cell response elements on the CSP protein have been mapped outside the repeat segments. In every experiment so far, the immunization experiments have been performed with large amounts of purified antigens.

35 It is the object of the present invention to provide modified proteins, such as Plasmodium falciparum proteins, which can elicit a strong immune response even if the parasite antigens are not purified. This approach is

interesting for the future developments of whole cell vaccines allowing less expensive but efficient immunization regimens.

According to the invention it has now been found  
5 that the addition of a glycosyl phosphatidylinositol (GPI) anchor to an antigen elicits a higher immune response than the corresponding antigen without the anchor.

The invention therefore provides recombinant polypeptides showing enhanced immunogenicity, comprising a  
10 glycosyl-phosphatidylinositol structure for eliciting an increased immune response as compared to corresponding polypeptides without the anchor. The polypeptide may be an antigen, preferably a parasite antigen, such as a Plasmodium falciparum antigen, like the P.falciparum circumsporozoite  
15 protein (CSP) or modified versions thereof.

In the description and the claims the use of the phrase "or modified versions thereof" intends to incorporate any derivative of the circumsporozoite protein showing sufficient immunogenicity to induce an immune response.  
20 Therefore not only the complete protein, but also fragments or mutated versions thereof are included.

The invention is illustrated herein by reference to the CSP protein of P.falciparum. However, the invention is not limited to this particular antigen. For the skilled  
25 person it will be a matter of routine to substitute the CSP by other desirable antigens thus obtaining the advantages of the invention without undue experimentation. The invention being based on the insight that the addition of a GPI-anchor to any polypeptide enhances the immunogenicity thereof.

30 Expression of CSP has been obtained in heterologous recombinant systems (E.coli, yeast, Vaccinia virus, baculovirus; Salmonella, Dictyostelium discoideum). It has been found that species of the slime mold Dictyostelium can be used as an efficient eukaryotic  
35 expression system for the production of recombinant proteins. Furthermore, compared to other expression systems, a complete stable CSP polypeptide may be produced in Dictyostelium (Fasel, N., Begdadi-Rais, C., Bernard, M.,

Bron, C., Corradin, G., and Reymond, C.D., (1992) Gene 111, 157-163). This system can thus be used to obtain a stronger and longer lasting immune protection since the complete CSP carries every B- and T-cell epitope.

5 Furthermore, Dictyostelium has biotechnological potential. It is a free-living organism, easy to grow and to maintain. Strains can grow on bacteria lawns with a doubling time of about 3 hours, in bacterial suspensions to high densities (up to  $10^{10}$  cells per liter) or in a semi-syn-  
10 thetic media containing glucose, peptone and yeast extract where doubling time is about 12 hours.

The life cycle of Dictyostelium consists of a growth and of a developmental phase. The developmental phase is triggered by starvation and is characterized by  
15 aggregation of previously single cells to form a multicellular organism which then differentiates to produce spores. In the presence of bacteria or rich medium spores germinate, leading to renewed growth. During this developmental cycle, diffusible factors are produced and for  
20 at least one of them (cAMP) binding to its receptor induces transcription of a set of specific genes (see Loomis, The Development of Dictyostelium discoideum, Acad. Press, 1982). Growth properties and transformation capacity of  
Dictyostelium discoideum offers the possibility to express  
25 foreign proteins, since cells can be grown at low cost on bacteria and expression of specific proteins can be tightly controlled by starvation in a simple medium. Finally, Dictyostelium discoideum is a safe, non-toxic, non-pathogenic free-living organism which could be a candidate  
30 for whole cell vaccine development if not for human at least for veterinary use.

Dictyostelium discoideum may thus be used for the production of the modified polypeptides of the invention, by transformation of the cells with a suitable vector,  
35 culturing the cells under circumstances allowing the expression of the polypeptide and optionally isolating the polypeptide. A suitable vector comprises a DNA sequence encoding the polypeptide, which DNA sequence is operatively

linked to a glycolipid anchor addition sequence located downstream thereof, and suitable transcription initiation and termination sequences operatively linked thereto. The DNA sequence preferably encodes a parasite antigen, such as  
5 a Plasmodium falciparum antigen, like the P.falciparum circumsporozoite protein (CSP) or modified versions thereof.

Many cell surface proteins in various organisms are anchored in the membrane lipid bilayer by a glycosyl phosphatidylinositol (GPI) structure. This complex structure  
10 is synthesized as a precursor glycolipid and transferred onto glycoproteins in the endoplasmic reticulum. The transfer of the preformed GPI anchor onto specific polypeptides is possible only if the appropriate signal sequence (herein also referred to as "glycolipid anchor  
15 addition sequence") is contained in the C-terminal region of target proteins. This signal sequence has been shown to be composed of a group of 10-12 residues upstream of a hydrophobic C-terminal sequence. In Dictyostelium, specific proteins have been shown to be anchored by a GPI. The C-  
20 terminal sequence determinants have been defined for one of these proteins, namely Contact site A (Noegel, A., Gerisch, G., Stadler, J. and Westphal, M. (1986) EMBO J. 5, 1473-1476). The GPI anchor once transferred to the polypeptide can be cleaved by specific phospholipases (GPI-phospholipase  
25 C or D), leading to a modification of the hydrophobic nature of the protein as detected by a different partitioning in a particular detergent, TX-114.

According to the invention the recombinant DNA vector therefore comprises a glycolipid anchor addition  
30 sequence which is derived from the D.discoideum Contact site A.

The invention further provides for a method of producing antibodies directed to one or more epitopes of a polypeptide, which method comprises the immunization of a  
35 suitable (e.g. mammalian) host with the polypeptide of the invention and optionally the subsequent isolation of the antibodies thus produced. As an alternative whole serum may be used. Preferably the polypeptide for immunization takes

the form of a whole cell lysate of a host cell expressing the polypeptide.

In this invention as an example, an immune response in mice was elicited by injecting whole cell  
5 lysates of Dictyostelium expressing glycosyl phosphatidylinositol anchored CSP. Furthermore, a specific immune response was obtained only when the CSP epitopes were linked to GPI, showing a potentiation of the immune response.

10 Furthermore, the present invention relates to a vaccine for immunization of mammalian hosts. The vaccine comprises the modified polypeptide of the invention in an immunoprotective amount, together with a suitable excipient. The immunoprotective amount comprises for example the  
15 polypeptide content of about  $1-5 \times 10^7$ , in particular  $2 \times 10^7$  host cells transformed with a vector encoding the polypeptide and the glycolipid anchor addition sequence.

The following example illustrates the present invention, but should not be considered as limiting the  
20 scope thereof.

### EXAMPLE

#### 1. Introduction

The following example teaches the production of  
25 Plasmodium falciparum CSP modified by addition of a glycolipid anchor in Dictyostelium discoideum and its use in immunization regimens. In more detail, the CSP polypeptide was expressed in the slime mould Dictyostelium discoideum by fusing a leader peptide and a glycosyl-phosphatidylinositol  
30 (GPI) addition signal sequence derived from the Dictyostelium contact site A.

Mice were immunized with Dictyostelium whole cell lysates expressing this GPI modified polypeptide. The antibodies raised recognized two different regions of the  
35 polypeptide. Thus, GPI modified polypeptides can be expressed in Dictyostelium cells. Both the polypeptides in isolated form and the cells comprising the polypeptides may

be used in immunization protocols having potentials for vaccination, diagnostic tests or basic studies.

## 2. Materials and methods

5 For the following experiments use is made of many techniques well known and accessible to those skilled in the art of molecular biology, protein chemistry and immunology. Such methods are not always described in details.

Enzymes are obtained from commercial sources and  
10 used according to supplier's protocols.

Bacterial media and current cloning techniques are described in Sambrook et al. (Molecular cloning: A Laboratory Manual, CSH press 1989)

Monoclonal antibodies and NANP<sub>50</sub> were obtained  
15 from F. Sinaglia (Hoffman La Roche Ltd, Basel)

## 3. Constructions of CS containing plasmids

### 3.1. pEDI-CS 49

Expression vector pEDI-CS is constituted of the  
20 pVEII vector (Maniak and Nellen, (1990) Nucl. Acids Res. 18, 5375) which contains the elements important for propagation and maintenance in a prokaryotic host (origin of replication and ampicillin resistance gene) and of a Tn903 encoded neomycin resistance gene conferring geneticin (G418)  
25 resistance to eukaryotic cells under the control of a Dictyostelium actin 15 transcription unit. The presence of a Discoidin 1 promotor allows the developmental control of expression of downstream sequences and actin 8 sequences insure proper termination of the RNA.

30 For construction of the pEDI-CS expression vector the HaeIII+RsaI restriction fragment of 1161bp of the CS NF54 gene (Caspers, P., Gentz, R., Matile, H., Pink, J.R., and Sinigaglia, F. (1989) Mol. Biochem. Parasitol. 35, 185-189) was first inserted into the Asp718+BamHI site of pVEII,  
35 after filling in by Klenow DNA polymerase. Subsequently both DNA strands of a sequence encoding the contact site A (CsA) leader peptide plus 3 amino acids were synthesized on an Applied Biosystem Model, 380 B DNA synthesizer. The

nucleotide sequence of the synthetic leader peptide is as follows:

5'-ATGTCTAGATTTTGTAGTATTGATAATATTATATAATATTTTAAATAG  
TGCACATTCAGCTCCAACCCAGGATCCATG-3'

5 and was confirmed by introducing the blunt end fragment into M13mp18 replicative form at the SmaI site, followed by DNA sequencing.

The XbaI/BamHI restriction fragment containing the CsA leader peptide was then isolated and inserted at the  
10 XbaI/BamHI sites present in the vector to generate expression vector pEDII-CS. In the pEDII-CS expression vector, the natural UAG stop codon of the CSP was replaced by the UAA stop codon. This was done by replacing most of the CSP coding region by a DNA fragment amplified using  
15 specific oligonucleotides as follows:

5' amplimer (placed downstream of the CsA leader peptide sequence and containing a BamHI site):

5'-ACCCAGGATACCCTTATTCCAG-3'

3' amplimer (corresponding to the last codons of the CSP  
20 gene but containing an UAA stop codon and a SacI site):

5'- AAAGCCGAGCTCTTAATTAAGGAACAAGAAGGATAAT-3'

These oligonucleotides carry specific restriction sites, BamHI and SacI, which are also present in the pEDII-CS and were used to replace the CSP gene segment of pEDII-CS. Using  
25 this strategy we obtained the expression vector pEDII-CS49 which produces a CSP protein with its original C-terminal polypeptide.

### 3.2. pERIV-CS

30 To express a GPI modified form of the CSP the plasmid pERIV-CS was constructed. This plasmid is derived from pERIV which itself is derived from pERII, a plasmid which is a combination of a Dictyostelium ras promoter fragment, a CsA signal peptide, an actin 6 termination  
35 sequence and of a neoR cassette in a pGEM3 vector. The neoR cassette, which comprises a Dictyostelium actin 15 promoter, the bacterial Tn903 resistance gene and a Dictyostelium actin 15 termination sequence were isolated from pDneo2

(Witke, W., Nellen, W., and Noegel, A. (1987). EMBO J. 6, 4143-4148) using EcoRV and inserted into pGEM3 (Promega corp.). The Dictyostelium ras promoter-CsA signal peptide fragment from pERI-CS (Fasel et al., supra) was then  
5 inserted in between the EcoRI and BamHI sites. The actin 6 termination sequence extracted from pDneo2 had first to be cloned into the HindIII site of pGEM4 (Promega corp.) to provide a second BamHI site, then to be re-isolated and inserted into BamHI site located next to the CsA signal  
10 peptide. The construct containing the actin 6 termination sequence in the proper orientation was called pERII. This plasmid was digested by EcoRV+XhoI and a DNA fragment obtained by amplification of a region coding for the glycosyl phosphatidylinositol anchor addition sequence was  
15 inserted using the appropriate sites. The two oligonucleotides used in the amplification have the following sequence:

5' ampimer (contains the EcoRV site):

5'-CCCGGTACCAGGCCTGATATCTCCAACCTCCAACCTGAAAC-3'

20 3' ampimer ( contains an XhoI site):

5'-CGGCTCGAGTTAAATTAATAAAACAAAAGAAATG-3'

The pERIV plasmid was digested by Asp718+EcoRV and the CSP NF54 allele was inserted. The CSP DNA, comprising the CSP gene but excluding the N-terminal signal peptide and the C-  
25 terminal hydrophobic CSP encoding segments, was obtained by amplification using the following ampimers:

5'ampimer (contains Asp718 site):

5'-CCCGGTACCATTATTCCAGGAATACCACTGC-3'

3' ampimer (contains an HaeIII site which can be fused to  
30 the EcoRV site):

5'-ATAGGCCACATTTTTCCATTTTACAAATTTTTTTTTTC-3'

The amplified DAN was inserted, after digestion with Asp718 and HaeIII between the Asp718 and EcoRV sites of pERIV. The plasmid obtained was designated pERIV-CS.

35

#### 4. Dictyostelium cell culture, transformation and expression

Dictyostelium cells were cultured in shaking suspensions in HL-5 medium up to  $5 \times 10^6$  cells/ml and starved in PDF (Pad Dilution Fluid) (Sussman, M. (1987) Methods in Cell Biology (Spudich, J.A., ed.) pp9-29, Acad. Press, Inc., 5 Orlando, FL). The various vectors were introduced by electroporation and expressing cells were selected as described in (Nellen, W., and Firtel, R.A. (1985) Gene 39, 155-163; Howard, P.K., Ahern, K.G., and Firtel, A. (1988) Nucleic Acids Res. 16, 2613-1623).

10 For Discoidin I promoter dependent expression, D.discoideum cells were starved for 4 hours in shaking suspension (160 rpm) in PDF at a density of  $5 \times 10^6$  cells/ml unless otherwise indicated (Fasel et al., supra).

For ras promoter constructs, the cells were  
15 starved for 6 hours in PDF at about  $5 \times 10^6$ /ml and transcription was induced by addition of 200  $\mu$ M cAMP and 10 nM DIF (Differentiation Inducing Factor) (Morris, H.R., Taylor, G.W., Massento, M.S., Jermyn, K.A., Kay, R.R. (1987), Nature 328, 811-814) for one hour unless otherwise  
20 stated (Louvion, J.F., Scholder, J.C., Pinaud, S., and Raymond, C.D. (1991) Nucleic Acids Res. 19, 6133-6138).

### 5. Protein analysis

The proteins from  $2 \times 10^6$  cells (per 4 mm wide  
25 slot), boiled in 1x Laemmli buffer for 5 min, were separated by 10% SDS-PAGE (Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) Molecular cloning: a laboratory manual., 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Proteins were electrotransferred onto nitrocellulose  
30 (Immunoblots). Fifty  $\mu$ g per ml of the anti-NANP monoclonal antibody (Sp3E9) (Boulanger, N., Matile, H., and Betschart, B. (1988) Acta. Tropica 45, 55-65) was added to the filter and incubated overnight at room temperature. Alkaline phosphatase conjugated protein A and chemiluminescence  
35 reaction (Amersham) were used to reveal anti-NANP binding.

### 6. GPI-phospholipase D assay

The GPI-PLD sensitivity of CSP modified with GPI was tested by lysing pERIV-CS cells in 20 mM Tris/HCl pH 7.5, 0.1M CaCl<sub>2</sub>, 0.008% TX-100 by four cycles of freezing and thawing. One or 5 units of GPI-PLD enzyme (Boehringer Mannheim) was added and the extracts incubated for 1 hour at 37°C. TX-114 in 1x TBS containing 1 mM EDTA was then added to a final concentration of 1% and the aqueous and detergent phases were separated. The samples were resolved on a 10% SDS polyacrylamide gel and analyzed by immunoblotting using the Sp3E9 monoclonal antibody as previously described.

### 7. ELISA

Serum and monoclonal antibodies produced against the N-terminal (amino acids 22-125), the NANP repeat peptide, or the C-terminal (amino acids 289-390) segment peptides were assayed by ELISA. Briefly, vinyl plates were coated with different peptides, washed and blocked with 1% BSA in PBS. Monoclonal or serum antibodies were serially diluted in 1% BSA/PBS containing 0.05% Tween 20. Diluted sera were added to antigen coated wells and incubated for 1 hour at room temperature. Plates were washed with PBS containing 0.05% Tween 20 and an appropriate dilution of peroxidase-conjugated species specific anti-IgG was added and incubated for 1 hr at room temperature. One hundred microliters of peroxidase substrate solution were added to each well and the A410 was determined. The end point of ELISA titers for the mice sera was designed to be the serum dilution producing an absorbance value 2 SD greater than the average of the control mice.

30

### 8. Immunization of animals and analysis of the antisera

Two times 25µl or one time 50µl of a 1:1 sonicated mixture of incomplete Freund's adjuvant and 2x10<sup>7</sup> cells were injected into Balb/c mice either subcutaneously or intraperitoneally, respectively. After 4 weeks, a boost was performed with an equivalent material, sera were collected 10 days afterwards, and analyzed by ELISA.

## 9. Results

For the development of a live vaccine, or diagnostic test, CSP modified by a GPI was expressed. The CSP-terminal hydrophobic segment (last 23 amino acids) was thus replaced by the last 49 amino acids of the Contact site A (CsA) polypeptide containing a GPI anchoring domain (Noegel et al., supra) (figure 1A and B). The CSP/CsA fusion gene was inserted under the control of the ras promoter (Louvion et al., supra, Fasel et al., supra). The construct was introduced into D. discoideum cells (pERIV-CS). Immunofluorescence using anti-CSP antibodies was used to ascertain presence of CSP at the surface of pERIV-CS cells (data not shown). Due to the use of the ras promoter, only 20 to 40% of the induced cells showed expression, which were those differentiating into prestalk cells (Reymond, C.D., Gomer, R.H., Mehdy, C., and Firtel, R.A. (1984) Cell 39, 141-148).

The CSP/CsA fusion protein produced in Dictyostelium discoideum has the amphiphilic character expected for a GPI modified protein (Bordier, C. (1981) J. Biol. Chem 256, 1604-1607, Conzelmann, A., Spiazzi, A., Hyman, R., and Bron, C. (1986) EMBO J. 5, 3291-3296) since it partitions in the TX-114 detergent phase (fig. 2). To confirm the presence of a GPI anchor on the CSP/CsA fusion protein, the cells were lysed by 3 cycles of freezing and thawing in 0.008% TX-100 and the cell lysates treated for 1 hour with 1 or 5 units of GPI-PLD. Removal of the lipidic portion of the CSP/CsA with 5 units of GPI-PLD altered its hydrophobic character and provoked its partitioning into the aqueous phase (fig. 2), whereas incubation with 1 unit had a limited effect. These results indicate the presence of a GPI structure on CSP expressed in Dictyostelium cells, thus indicating that D. discoideum can produce, process and modify heterologous parasite proteins by adding a GPI anchor.

To assess the ability of the GPI modified CSP to induce an immune response, 8 Balb/c mice were immunized subcutaneously or intraperitoneally with  $2 \times 10^7$  whole cells

mixed with incomplete Freund's adjuvant. Ten days after a second injection, the humoral immune response was analyzed by ELISA against synthetic peptides from different regions of the CSP (Table 1). Antibodies were detected against the immunodominant NANP repeat region, against the C-terminal non repetitive region (amino acids 289-390), but not against the N-terminal 22-125 synthetic peptide. Interestingly, presence of specific antibodies and antibody titers were not influenced by the route of injection (Table 1). As control experiments mice were injected with Dictyostelium cells expressing the CSP synthesized by the pEDII-CS49. In this case, the CSP has its original peptidic C terminal segment and is not modified by a GPI anchor. No antibodies directed against different segments of CSP (Table 2) were detected in ELISA.

#### 10. Figure legends

FIG.1 Circumsporozoite protein (CSP) expression vectors

A. A detailed description on the generation of these two vector is given in the text. Briefly, CSP lacking its first 18 amino acids was fused in frame to the CsA leader peptide leading to pEDII-CS and replacement of the original P.falciparum UAG to UAA resulted in construct pEDII-CS 49. pERIV-CS was derived from pERII (see text) which contains the Tn5 neoR gene between actin 15 promoter and termination sequences. The GPI anchoring domain of the CsA protein was placed in frame at the C-terminus of CSP (see panel B). Symbols: "Discoidin I" and "ras" are sequences promoting transcription in Dictyostelium. Arrows indicate transcription start sites. I, II and III indicate highly conserved domains of the CSP.

B. In pERIV-CS, the CSP hydrophobic domain was replaced by the last 49 amino acids of the CsA protein. An extra proline (P) was added during cloning between the CSP (underlined) and CsA sequences.

FIG. 2. Phospholipid modification of CSP expressed in Discoideum cells

Proteins extracted from about  $2 \times 10^6$  cells were treated by GPI-PLD with 1 (lanes 1) or 5 units for one hour (lanes 5), submitted to a TX-114 phase separation (Bordier, supra) and analyzed by immunoblot. Briefly, stably transformed cells were lysed and separated by SDS PAGE and proteins were transferred onto nitrocellulose. CSP was revealed by immunodetection using (NANP)<sub>50</sub> monoclonal antibody Sp3E9.

The apparent molecular mass of the CSP (62kDa) was estimated using molecular mass standards. Molecular mass standards were as follows: phosphorylase b (97 kDa), bovine serum albumin (66 kDa), egg white ovalbumin (42.7) kDa). Aq: Aqueous phase, Tx: TX-114 detergent phase. 0: samples not treated by GPI-PLD.

# 11. Tables

Table 1: ELISA of sera<sup>a</sup> of pERIV-CS immunized mice with (NANP)<sub>50</sub>, M1 (189-390) peptides.

	Animal	(NANP) <sub>50</sub>	M1 (289-390)
		ELISA titer	ELISA titer
25	B(ip) <sup>b</sup>	1/1000	1/900
	G(sc)	1/5000	1/900
	R(ip)	1/5000	1/900
	Y(sc)	1/1000	1/300
	Y(ip)	1/5000	1/300
	W(ip)	1/1000	1/900
30	Control <sup>c</sup>	<1/10	<1/10

<sup>a</sup>sera were obtained 7 days after a single boost of Balb/c mice immunized with  $2 \times 10^7$  cells

<sup>b</sup>mice were immunized either subcutaneously (sc) or intraperitoneally (ip)

<sup>c</sup>control animal was injected with incomplete Freund's adjuvant alone

5 **Table 2:** Elisa of sera<sup>a</sup> of pEDII-CS 49 immunized mice with (NANP)<sub>50</sub>, M1 (289-390) and M2 (22-125) peptides.

	Animal	(NANP) <sub>50</sub>	M1(289-390)	M2(22-125)
		ELISA titer	ELISA titer	ELISA titer
10	Nr.1 <sup>b</sup>	<1/10	<1/10	<1/10
	Nr.2	<1/10	<1/10	<1/10
	Nr.3	<1/10	<1/10	<1/10
	Control <sup>c</sup>	<1/10	<1/10	<1/10

15

<sup>a</sup>sera were obtained 7 days after a single boost of Balb/c mice immunized with  $2 \times 10^7$  cells

<sup>b</sup>mice were immunized either subcutaneously (sc) or intraperitoneally (ip)

20 <sup>c</sup>control animal was injected with incomplete Freund's adjuvant alone

## CLAIMS

1. Recombinant polypeptide showing enhanced  
5 immunogenicity, comprising a glycosyl-phosphatidylinositol structure.
2. Polypeptide as claimed in claim 1, wherein the polypeptide is an antigen.
3. Polypeptide as claimed in claim 2, wherein the  
10 antigen is a parasite polypeptide.
4. Polypeptide as claimed in claim 3, wherein the parasite antigen is a Plasmodium falciparum polypeptide.
5. Polypeptide as claimed in claim 4, wherein the Plasmodium falciparum antigen is the circumsporozoite  
15 protein (CSP) or modified versions thereof.
6. Recombinant DNA vector for expressing the polypeptide as claimed in any one of the claims 1-5, comprising a DNA sequence encoding the polypeptide, which DNA sequence is operatively linked to a glycolipid anchor  
20 addition sequence located downstream thereof, suitable transcription initiation and termination sequences and optionally a leader peptide sequence, all operatively linked thereto.
7. Recombinant DNA vector as claimed in claim 6,  
25 wherein the DNA sequence encodes a parasite antigen.
8. Recombinant DNA vector as claimed in claim 7, wherein the parasite antigen is a Plasmodium falciparum antigen.
9. Recombinant DNA vector as claimed in claim 8,  
30 wherein the Plasmodium falciparum antigen is the circumsporozoite protein (CSP) or modified versions thereof.
10. Recombinant DNA vector as claimed in any one of the claims 6-9, wherein the glycolipid anchor addition sequence is derived from the D.discoidium Contact site A.
- 35 11. Recombinant host cell comprising a recombinant DNA vector as claimed in any one of the claims 6-10.
12. Recombinant host cell as claimed in claim 11, wherein the host is a Dictyostelid host.

13. Recombinant host cell as claimed in claim 12, wherein the Dictyostelid host is a Dictyostelium species, in particular Dictyostelium discoideum.

14. Method of inducing an immune response directed  
5 to one or more epitopes of a polypeptide, which method comprises the immunization of a mammalian host with the polypeptide as claimed in any one of the claims 1-5 and the subsequent isolation of the antibodies thus produced.

15. Method as claimed in claim 14, wherein the  
10 polypeptide for immunization takes the form of a whole cell lysate of a host cell expressing the polypeptide.

16. Method for the production of the modified polypeptides as claimed in claims 1-5, by transformation of suitable host cells with a suitable vector as claimed in  
15 claims 6-10, culturing the cells under circumstances allowing the expression of the polypeptide and optionally isolating the polypeptide.

17. Vaccine, comprising the polypeptide as claimed in any one of the claims 1-5 in an immunoprotective amount,  
20 together with a suitable excipient.

18. Vaccine as claimed in claim 17, wherein the immunoprotective amount comprises the polypeptide content of about  $1-5 \times 10^7$ , in particular  $2 \times 10^7$  host cells as claimed in claim 11-13.

Fig. 1 A




Fig. 1 B

...KKICKMEKCG PTPETA'TPSPTP...

2/2




Fig. 2

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/01744

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/30 C12N15/85 C07K14/445 A61K39/015

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF IMMUNOLOGY, vol. 142, no. 3, 1 February 1989, BALTIMORE US, pages 979-984, XP002010529 PEARCE E. J. ET AL.: "Three major surface antigens of Schistosoma mansoni are linked to the membrane by glycosylphosphatidylinositol" see page 983, left-hand column ---	1
A	J BIOL CHEM 266 (19). 1991. 12242-12248, XP002010530 VAI M ET AL: "ISOLATION AND DEDUCED AMINO ACID SEQUENCE OF THE GENE ENCODING GP115 A YEAST GLYCOPHOSPHOLIPID-ANCHORED PROTEIN CONTAINING A SERINE-RICH REGION." see the whole document --- -/--	1-18



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

9 August 1996

Date of mailing of the international search report

20.08.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Moreau, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/01744

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,92 20806 (RMF DICTAGENE) 26 November 1992 see the whole document ---	1-18
P,X	JOURNAL OF BIOLOGICAL CHEMISTRY 270 (21). 1995. 12941-12947, XP002010531 REYMOND C D ET AL: "Anchoring of an immunogenic Plasmodium falciparum circumsporozoite protein on the surface of Dictyostelium discoideum." see the whole document ---	1-18
P,X	WO,A,95 22614 (FINEP-FINANCIADORA DE ESTUDOS E PROJETOS) 24 August 1995 see the whole document -----	1,2,6, 10-18

## INTERNATIONAL SEARCH REPORT

I national application No.

PCT/EP 96/ 01744

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: X  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 14 - 15 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/01744

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9220806	26-11-92	NL-A- 9100869	16-12-92
		AU-B- 657966	30-03-95
		AU-B- 1884492	30-12-92
		EP-A- 0540719	12-05-93
		HU-A- 69139	28-08-95
		JP-T- 6501621	24-02-94
		ZA-A- 9203597	02-06-93
-----			
WO-A-9522614	24-08-95	BR-A- 9400600	24-10-95
-----			